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Abstract
IgG antibodies can organize into ordered hexamers on cell surfaces after binding their anti-
gen. These hexamers bind the first component of complement C1 inducing complement-
dependent target cell killing. Here, we translated this natural concept into a novel technol-
ogy platform (HexaBody technology) for therapeutic antibody potentiation. We identified
mutations that enhanced hexamer formation and complement activation by IgG1 antibodies
against a range of targets on cells from hematological and solid tumor indications. IgG1
backbones with preferred mutations E345K or E430G conveyed a strong ability to induce
conditional complement-dependent cytotoxicity (CDC) of cell lines and chronic lymphocytic
leukemia (CLL) patient tumor cells, while retaining regular pharmacokinetics and biophar-
maceutical developability. Both mutations potently enhanced CDC- and antibody-depen-
dent cellular cytotoxicity (ADCC) of a type II CD20 antibody that was ineffective in
complement activation, while retaining its ability to induce apoptosis. The identified IgG1 Fc
backbones provide a novel platform for the generation of therapeutics with enhanced effec-
tor functions that only become activated upon binding to target cell–expressed antigen.
Author Summary
Immunotherapy is a powerful and rapidly expanding field that makes use of the body’s
natural defense mechanisms to eliminate disease entities such as infectious agents or can-
cer cells. Circulating antibodies bind aberrant structures in a highly target-specific manner
PLOS Biology | DOI:10.1371/journal.pbio.1002344 January 6, 2016 1 / 24
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and “flag” disease cells for destruction by killing machineries that are present in the blood-
stream. We recently showed that activation of one of these immune defense mechanisms,
the complement system, is most efficiently initiated by binding of the first complement
component C1q to a ring of six antibodies. Since antibody hexamerization occurs naturally
only after binding to surface antigens, complement activation and subsequent comple-
ment-mediated cell killing is therefore restricted to these antibody-flagged cells. Now, with
a mutational screening approach, we identified structural entities in the antibody back-
bone that potentiate this antigen binding–induced hexamer formation. We identified
mutations that enhance the hexamer formation and complement activation by IgG1 anti-
bodies against a wide range of targets on varying cancer cells. Based on our findings, we
present a broadly applicable platform for the generation of therapeutic antibodies with
enhanced ability to promote hexamerization-induced complement activation and target
cell killing only after surface antigen binding.
Introduction
Target cells are flagged for destruction by antibodies bound to their cognate antigen on the cell
surface. Elimination of antibody-opsonized cells is mediated by the innate immune system. The
cellular branch of this system includes NK cells, monocytes, macrophages, and neutrophils that
are activated via specific IgG Fc receptors (FcγR) sensing surface-bound IgG antibodies. The
molecular branch of innate defense includes the complement system, which consists of an
amplifiable cascade of soluble zymogens that are abundant in blood and other extracellular flu-
ids. We recently showed that IgG antibodies organize into ordered hexamers on cell surfaces fol-
lowing antigen binding. These IgG hexamers bind and activate C1, the first component in the
classical complement pathway that leads to target cell killing by complement-dependent cyto-
toxicity (CDC) via membrane attack complexes (MACs) that breach the cell membrane [1]. In
addition, complement activation generates chemoattractants, anaphylatoxins, and opsonins
that serve to attract and activate immune effector cells and induce additional killing [2]. In
immunotherapy, we leverage these natural defense mechanisms by marking specific target cell
populations for elimination by passively administered therapeutic antibodies. These antibodies
may be engineered to enhance their ability to activate effector cells or complement. For example,
amino acid residues in IgG that affect binding in an FcγR-specific fashion can be modified to
promote more efficient antibody-dependent cellular cytotoxicity (ADCC) or antibody-depen-
dent cellular phagocytosis [3–5]. C1 binding and CDCmay be increased by reshuffling IgG1
and IgG3 or by mutating amino acid positions adjacent to the lower hinge [6–11]. In contrast to
IgG molecules, IgM antibodies already pre-exist as pentameric or hexameric oligomers that are
kept together via covalent bonds. Exposure of the C1 binding site and the activation of comple-
ment is regulated via conformational changes upon antigen binding [12,13]. This concept to
enhance complement activation has been exploited by the covalent association of IgG mono-
mers via disulfide bonds between cysteine residues in an IgM-derived 18 amino acid carboxy-
terminal extension and additionally between cysteine residues introduced at position 309 [14].
The ability and potency of monoclonal antibodies (mAbs) to induce complement activation
and CDC is dependent on IgG isotype and on the characteristics of both the antigen (i.e., size,
flexibility, and mobility) and the epitope (i.e., accessibility and distance to the membrane). The
potential of complement for rapid and effective cell killing, as well as its capacity for attracting
and modulating both innate and adaptive cellular immune responses, provide a strong rationale
for the development of therapeutic antibodies with optimized complement-activating
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characteristics [2]. However, few therapeutic antibodies generated to date induce potent CDC
[2,15–17], and the availability of technologies to facilitate the generation and development of IgG
antibodies that are capable of effective complement activation are therefore highly sought after.
We recently demonstrated that the assembly of IgG molecules into hexamers may be
enhanced by specific mutations in the Fc domain [1]. Here, we identify two preferred IgG1
backbones, harboring a single amino acid mutation, that strongly enhance Fc-mediated assem-
bly at the cell surface, while retaining all the qualities required for the development of biophar-
maceuticals. We demonstrate applicability to a range of targets and cells including
hematological and solid tumor indications as well as cell lines and patients’ cells. The condi-
tional nature of the technology provides a novel route for the identification and safe develop-
ment of potentiated Fc-based immunotherapeutics.
Results
Potentiation of CDC Activity by Increased Hexamerization Is Broadly
Applicable
Previously, we showed that antigen-bound IgG molecules organize into hexamers at the cell
surface to mediate optimal C1q binding and complement activation. We observed an extensive
Fc:Fc interface between IgG molecules, and it was shown that a glutamic acid into arginine
(E345R) mutation at this interface enhanced IgG clustering, C1q binding, and CDC [1]. To
determine whether this observation could be broadly applied, we introduced the E345R muta-
tion in a panel of IgG antibodies targeting different antigens (CD20 [Uniprot P11836], CD52
[P31358], CD38 [P28907], and epidermal growth factor receptor [EGFR] [P00533]) and
assessed CDC of cell lines with varying expression of antigen and membrane complement reg-
ulatory proteins (mCRPs) CD46 (P15529), CD55/DAF (P08174), and CD59 (P13987).
Introduction of the E345R mutation into the chimeric CD20 antibody rituximab (RTX) as
well as the human CD20 antibody 11B8 increased lysis of both Wien 133 and Daudi cells (Fig
1, S1 Table). The difference was particularly apparent for wild-type 11B8, which, as expected
for a type II CD20 antibody, did not induce complement-mediated lysis (Fig 1A). Introducing
E345R in the CD52 antibody alemtuzumab (ALM) strongly enhanced CDC of both Wien 133
and Raji cells (Fig 1B), and the mutation also potentiated both the CD38 antibodies IgG1-005
and IgG1-003 (Fig 1C). Interestingly, antibody 2F8 directed against the solid-tumor antigen
EGFR also induced potent CDC when containing E345R (Fig 1D). IgG1-003 and 2F8 represent
antibodies that were unable to induce CDC in previous studies [18,19]. From these data, we
conclude that the Fc:Fc interface mutation E345R is able to convert antibodies against a range
of targets and epitopes into potent mediators of CDC, even for antibodies that do not induce
any complement-mediated lysis as a wild-type IgG1 molecule.
To analyze the impact of target expression, we performed CDC assays using a panel of
human tumor cell lines with increasing CD20 expression. Cells were selected for a comparable
(intermediate) expression of total mCRPs resulting in increasing CD20:mCRP ratios (S2
Table). Only highly CD20-overexpressing SU-DHL-4 cells were lysed efficiently by RTX,
whereas lower expression resulted in minimal lysis. In contrast, introduction of E345R in RTX
yielded strong lysis for all three cell lines tested (Fig 2A). The potential of mCRPs to limit CDC
by wild-type and E345R-mutated RTX was assessed with cell lines that express similar levels of
the CD20 target antigen and increasing levels of mCRPs, resulting in decreasing CD20:mCRP
ratios (Fig 2A, S2 Table). RTX-E345R demonstrated increased lysis for all cell lines tested, indi-
cating that the mutation reduced sensitivity to mCRP inhibition.
The in vivo efficacy of E345R-potentiated IgG1 antibody 7D8, directed against CD20, was
evaluated in severe combined immunodeficiency (SCID) mice inoculated subcutaneously with
Therapeutic Antibody Potentiation by Antigen-Dependent Hexamerization
PLOS Biology | DOI:10.1371/journal.pbio.1002344 January 6, 2016 3 / 24
Fig 1. CDC enhancement by promoting Fc:Fc interactions is broadly applicable. A representative example of three replicates is shown. Each graph
compares CDC in dose response for the wild-type and E345R-mutated mAb. (A) CDC of Wien 133 (left) and Daudi cells (right) opsonized with anti-CD20
mAbs RTX and 11B8. (B) CDC of Wien 133 (left) and Raji cells (right) opsonized with anti-CD52 mAb ALM. (C) CDC of Wien 133 cells (left) and Daudi cells
(right) opsonized with anti-CD38 mAbs IgG1-003 and IgG1-005. (D) CDC assay of A431 cells opsonized with anti-EGFRmAb 2F8.
doi:10.1371/journal.pbio.1002344.g001
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luciferase-expressing Raji cells expressing high numbers of complement defense molecules
(Fig 2B). After the tumor volume reached approximately 40–150 mm3, mice were randomized
at an average tumor volume of 85 mm3 per group and treated intraperitoneally with a single
dose of 50 μg 7D8, 7D8-E345R, 7D8-K322A, or an irrelevant IgG1 isotype control antibody
(IgG1-b12). 7D8-K322A contains a mutation that abrogates C1q binding and CDC and was
used as an additional control. In agreement with its increased ability to activate complement,
only 7D8-E345R showed significant antitumor efficacy. The wild-type 7D8 showed a trend of
activity, but did not reach statistical significance compared to controls. Statistical analysis of
tumor inhibition was performed on day 22 when all mice in all groups were still in the study
Fig 2. Promoting Fc:Fc interactions alleviates CDC sensitivity to target andmCRP expression. (A) Cell lines were opsonized with saturating amounts
of wild-type or mutated RTX and analyzed by CDC assay. Left panel: cell lines with increasing CD20:mCRP ratio (left to right); right panel: cell lines with
decreasing CD20:mCRP ratio (left to right). (B) In vivo analysis of subcutaneous tumor growth in a severe combined immunodeficiency (SCID) xenograft
model. SCID mice were injected with luciferase-expressing Raji cells. Eight days after tumor cell injection, mice were randomized at an average tumor
volume of 85 mm3 per group and treated with 50 μg IgG1 antibody. Tumor volumes were monitored over time and depicted as average tumor
volume ± standard error of the mean (SEM) (left panel), and as Kaplan-Meier curves with time to progression cutoff set at a tumor volume of >700 mm3 (right
panel).
doi:10.1371/journal.pbio.1002344.g002
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(S3 Table). 7D8-E345R inhibited tumor growth vs control (p = 0.0044) and compared to
7D8-K322A (p = 0.0474). In addition, in a Kaplan Meier analysis performed until the end of
the experiment on day 44 (S3 Table and Fig 2B), 7D8-E345R significantly inhibited progression
as defined by tumors growing> 700 mm3 (p = 0.019), whereas the wild type did not.
Library Screening Demonstrates All Mutations of E345 and E430
Stimulate CDC
To better understand the structural constraints of IgG hexamerization and to identify mutations
other than E345R that promote Fc:Fc interactions, we generated an antibody mutant library
focused on two regions of interest. Firstly, amino acid substitutions were introduced at, or proxi-
mal to, the intermolecular Fc:Fc interface observed in the hexameric crystal packing of human
IgG1 [1,20]. Secondly, amino acid substitutions were introduced at the intramolecular CH2–CH3
interface to alter Fc domain flexibility, which could potentially modulate Fc:Fc interactions allo-
sterically (Fig 3A). We employed screening conditions that allowed for the identification of inhib-
itory and stimulatory mutations. Mutants of CD38 antibody IgG1-005 containing single amino
acid mutations were screened with the complement-sensitive cell line Daudi at a concentration
that induced maximal lysis for the wild-type antibody to identify inhibitory positions (Fig 3B; S4
Table). Stimulatory mutations were screened for using the complement-refractory cell line Wien
133 at a concentration that induced minimal CDC for the wild-type antibody (Fig 3C, S5 Table).
As shown by the orange- and red-colored residues in Fig 3B and S4 Table, most mutations
at the Fc:Fc interface inhibited CDC, corroborating our previous observations [1] and confirm-
ing that Fc:Fc interactions are a prerequisite for efficient complement activation. The consen-
sus IgG interaction site for FcRn, Protein A, and Protein G (S1A Fig) [21] was found to play a
crucial role in the interaction between antibody Fc domains, as exemplified by the abundance
of CDC-inhibiting mutations in this region (S1B Fig). The C-terminal β-strand represents
another critical region as mutations of all amino acids in the stretch 437–440 inhibited CDC,
demonstrating it provides important contacts for an efficient Fc:Fc interaction (S1C Fig).
Mutations promoting Fc:Fc interactions were relatively sparse and predominantly confined
to the periphery of direct Fc:Fc contacts as indicated by the green colored residues in Fig 3C
and S5 Table. A selection of the stimulating mutations were separately introduced in RTX and,
next to the IgG1-005 mutants, assessed in dose response. This analysis demonstrated that the
E345, E430, and S440 mutations that enhanced CDC of Wien 133 cells by IgG1-005 (Fig 3D)
also consistently stimulated CDC of Ramos cells by RTX (Fig 3E) and Daudi cells by IgG1-005
and RTX variants (S2 Fig, S6 and S7 Tables).
The observation that all mutations at amino acid positions E345 and E430 stimulate CDC is
surprising (S5 Table). A close-up of the structure surrounding the E345 Fc:Fc interface residue
shows that its side chain is directed towards residue G385 at the terminus of CH3 β-strand C of
the facing antibody (Fig 3F), according to the Ig fold nomenclature of Halaby [22]. Residue
E430 forms a salt bridge stabilizing the CH2–CH3 interface packing (Fig 3G). Since even con-
servative mutations into aspartic acid, preserving the negative charge, resulted in enhanced
CDC, glutamic acid residues at these positions appear to restrain IgG molecules in a conforma-
tion that inhibits Fc:Fc interactions and CDC. In summary, a number of CDC-enhancing point
mutations were identified, with amino acids E345 and E430 acting as hotspots controlling anti-
body hexamerization and complement activation.
Solution-Phase Complement Activation and Pharmacokinetics
For therapeutic application of the mutants, nonspecific complement activation in the extracel-
lular fluid is undesired and hexamerization should therefore only occur after the antibody
Therapeutic Antibody Potentiation by Antigen-Dependent Hexamerization
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Fig 3. E345 and E430 limit Fc:Fc interactions. (A) Left: overview of the IgG1 antibody hexamer observed in the IgG1-b12 crystal structure (PDB access
code 1HZH [20]). Right: zoomed-in view of two neighboring Fc domains with enhancing amino acid positions highlighted. (B) Summary of CDC inhibition
data. The surface view is rotated 90° relative to panel A to show the Fc:Fc interface. Daudi cells were opsonized with mutants of anti-CD38 mAb IgG1-005
(1.0 μg/mL) and assessed for CDC. Light and dark grey colors indicate the unmodified amino acids of the two heavy chain regions composing a single Fc
domain. All mutants assessed were ranked by efficiency per amino acid position, and the resulting median lysis efficacy is indicated by coloring per position;
Therapeutic Antibody Potentiation by Antigen-Dependent Hexamerization
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binds its target at the cell surface. We therefore incubated the panel of mutants in human
serum (90%) at a high, 100 μg/ml, concentration, and we assessed the generation of comple-
ment activation product C4d (Fig 4A). C4d generation by heat aggregated IgG (HAG) was
used as a positive control. Complement activation, indicative of hexamer formation in solution,
was only observed for mutants E345R and E430F, whereas all others did not induce C4d
generation.
To fully exclude hexamerization in vivo, we used pharmacokinetic analyses in C.B-17 SCID
mice as an additional assessment. Larger molecular species of IgG, potentially interacting with
C1, would be expected to clear more rapidly than monomeric IgG molecules. The observed
clearance rates in mice were consistent with the observed C4d generation in human serum (Fig
4B). Whereas mutants E345R and E430F displayed somewhat faster clearance rates, the other
variants displayed clearance rates similar to wild-type IgG1-005. These findings were corrobo-
rated by the pharmacokinetic behavior observed for RTX variants (S3 Fig).
Biophysical Characterization of Antibody Hexamerization in Solution
To assess the suitability of the IgG mutants for their potential development as biopharmaceuti-
cals, we analyzed their biophysical characteristics with an emphasis on methods that could
detect solution-phase multimers. Firstly, we analyzed the mutants by native mass spectrometry
orange and red colors indicate positions with reduced lysis. Blue: >60% lysis; orange: 30%–60% lysis; red: <30% lysis. (C) Summary of CDC enhancement
data. Wien 133 cells were opsonized with mutants of anti-CD38 mAb IgG1-005 (1.0 μg/mL) and assessed for CDC. Light and dark grey colors indicate
unmodified amino acids as described under (B). The maximal lysis of the most efficient mutant per amino acid position is displayed with green indicating
positions for which CDC was enhanced. Blue: <20% lysis; light green: 20%–40% lysis; dark green: >40% lysis. (D) Dose response in CDC of Wien 133 cells
by IgG1-005 and selected mutants. A representative of 3 replicate experiments is shown. (E) Dose response in CDC of Ramos cells induced by RTX and
selected mutants. A representative experiment of 3 replicates is shown. (F) Structural view zoomed to residue E345. Amino acids facing E345 at the Fc:Fc
interface are indicated in blue and named with apostrophe. (G) Structural view zoomed to residue E430, forming a salt bridge with K338 at the intramolecular
CH2–CH3 domain interface.
doi:10.1371/journal.pbio.1002344.g003
Fig 4. Specific IgGmutations retain fluid phase complement suppression and regular pharmacokinetics. (A) C4d ELISA of IgG1-005 mutants
detecting solution-phase complement activation in serum. The background (BKG) C4d level in serum is indicated with a dashed line. Results were averaged
over three experiments. (B) PK analysis of IgG1-005 mutants in SCID mice, using three mice per group. Clearance of a single 500 μg dose of mAb was
monitored for three weeks and is expressed as 1,000 * Dose / area under the curve (AUC); dashed line: clearance of wild-type IgG1-005.
doi:10.1371/journal.pbio.1002344.g004
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(MS) [23]. Similar to wild-type IgG1-005, the mutants E345K and E430G only showed a charge
envelope aroundm/z of 5,500, corresponding to a 147 kDa molecular weight (Mw) IgG mono-
mer. Mutant E345R, in contrast, yielded an additional charge envelope aroundm/z of 12,500,
corresponding to an 890 kDa Mw demonstrating that it forms some hexamers in solution,
albeit at very low abundance (1.2% of total antibody mass) (Fig 5A). As a reference, we used
the triple mutant IgG1-005-E345R/E430G/S440Y (RGY) that was previously shown to form
hexamers in solution by HP-SEC, native MS and cryo electron tomography [1]. An
E345R-E430G double mutant and the RGY triple mutant displayed a further increase in solu-
tion-phase hexamer formation, amounting to about 7.7% and 73% of total antibody mass,
respectively. We were unable to detect single mutant species with increased Mw by high-per-
formance size exclusion chromatography (HP-SEC) as well as multiangle laser light scattering
analysis of hollow fiber flow field-flow fractionation separated fractions (S4 Fig).
To obtain sufficient material for the analysis of highly concentrated mAb solutions, we next
generated three stable CHO cell lines producing 7D8 wild-type and the mutants E345K and
E430G. Purified antibodies were concentrated to 100 mg/mL and analyzed by dynamic light
scattering (DLS), since it is exquisitely sensitive to the presence of high molecular weight spe-
cies and tolerates highly concentrated protein solutions. Regression analysis of the diffusion
coefficient [24] demonstrated slightly increased attractive interactions for both the E345K and
E430G mutant (−17.4 x 10−3 mLg−1 and −12.6 x 10−3 mLg−1, respectively) compared to wild-
type 7D8 (−7.57 x 10−3 mLg−1) (Fig 5B). At concentrations above 10 mg/ml, the Rhs of the
two mutants increased more strongly than the wild-type antibody (Fig 5C). To assess whether
these slightly increased self-interactions impacted the stability of highly concentrated liquid
antibody formulations, 100 mg/ml formulations in PBS of 7D8 and the mutants were incu-
bated at 5°C for three months and monitored by biophysical methods (Fig 5D, S5 Fig). The
aggregation and other biophysical characteristics for both mutants could not be distinguished
from the wild-type IgG1, indicating that the increased self-interactions at high concentration
were fully reversible.
Effector Functions of IgG Mutants with Enhanced Fc:Fc Interactions
The potential of the IgG1-E430G and IgG1-E345K mutants was further assessed by studying
anti-CD20 antibody 11B8, for which we could address the impact of hexamerization-enhanc-
ing mutations on CDC, ADCC, as well as the induction of programmed cell death (PCD). The
type II CD20 antibody 11B8 induces ADCC and PCD (in the absence of exogenous crosslink-
ing), but not CDC. Consistent with the data above, both the E345K- and the E430G-mutated
11B8 induced potent CDC, whereas the wild-type antibody did not (Fig 6A). Interestingly, the
ability of 11B8 to induce ADCC was also significantly improved by both mutations (Fig 6B).
To study PCD induction by 11B8, Daudi cells were stained for Annexin V (P08758) positivity
and active, cleaved Caspase 3 (P42574, Fig 6C). The magnitude of PCD was similar to that
induced by the wild-type 11B8 antibody and to obinutuzumab (OBN) that was used as a posi-
tive control. In summary, both the E430G- and E345K-mutated IgG1 displayed increased CDC
and ADCC, while retaining the type II CD20 antibody-specific ability to induce PCD.
Efficient Lysis of CLL Patient Tumor Cells
Based on their strong enhancement of antigen-dependent CDC, favorable biophysical charac-
teristics, stability, monomericity, absence of solution-phase complement activation, regular
pharmacokinetics, and retained effector functions, we selected IgG1-E430G and IgG1-E345K
as the preferred mutants. The therapeutic potential of these mutant IgGs was assessed in ex
vivo CDC assays with tumor cells obtained from patients with chronic lymphocytic leukemia
Therapeutic Antibody Potentiation by Antigen-Dependent Hexamerization
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Fig 5. Biophysical characterization of antibody hexamerization in solution. (A) Native MS analysis of solutions of IgG1-005 and mutant antibodies at
2 μM. IgG1-005-RGY (RGY), a previously described triple mutant, is used as a positive control. The charge envelope of the IgGmonomers appears around
m/z 5,500 (~ 147 kDMw) and that of the IgG hexamers aroundm/z 12,500 (~890 kDMw). The signals of the hexameric species are displayed at a 100-fold or
10-fold (RGY only) amplification. (B–C) Dynamic light scattering analysis of 7D8 and mutant solutions formulated in PBS pH 7.4. Three independent
experiments are shown. (B) Linear regression of diffusion coefficient versus Ab concentration. (C) Hydrodynamic radii (Rhs) of mutants measured by
dynamic light scattering (DLS) were divided by Rh of wild-type 7D8 to correct for viscosity without masking the contribution of Fc:Fc self-association. (D)
HP-SEC analysis of 100 mg/mL 7D8 and mutant antibody solutions formulated in PBS, incubated for three months at 5°C. Multimer detection limit of 1% is
indicated by a dashed line.
doi:10.1371/journal.pbio.1002344.g005
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Fig 6. Anti-CD20 antibodies can be enhanced for CDC activity while enhancing or retaining other effector functions. (A) Daudi cells (left) or Raji cells
(right) were opsonized with wild-type or mutant 11B8 and analyzed in CDC assays. A representative of three replicate experiments is shown. (B) Raji cells
were opsonized with wild-type or mutant 11B8 and analyzed in ADCC assays using PBMCs isolated from two individual donors (donor 1, FcγRIIa H/H &
FcγRIIIa V/V [14% NK cells]; donor 2, FcγRIIa R/R & FcγRIIIa V/F, [8% NK cells]). Two representative examples of five donors are shown. (C) Daudi cells
were opsonized with wild-type or mutant 11B8 and assessed for PCD by (left) Annexin V staining and (right) cleaved Caspase 3. 11B8, 11B8-345K,
11B8-E430G and OBN are significantly different from IgG1-b12 (three replicate experiments, one-way Anova p < 0.05).
doi:10.1371/journal.pbio.1002344.g006
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(CLL). Patient CLL cells usually are relatively resistant to anti-CD20-induced CDC due to their
low CD20 and high mCRP expression [16]. Interestingly, the E345K and E430G mutations,
introduced into CD20 mAb 7D8, provided strongly enhanced CDC of patient cells (Fig 7).
Moreover, both mutations enabled killing of 5 out of 6 patient CLL cells by RTX, where wild-
type RTX was unable to induce CDC.
Fig 7. Efficient lysis of CLL patient tumor cells. Peripheral B cells isolated from the blood of six CLL patients were opsonized with wild-type or mutant,
7D8, RTX or control (IgG1-b12) antibody and tested in CDC assays. The CLL cells of patient 4 were highly refractory to CDC due to their very low CD20
expression.
doi:10.1371/journal.pbio.1002344.g007
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Discussion
Activation of complement factor C1 by IgG antibodies via the classical pathway requires anti-
gen binding and hexamerization of the antibody at the cell surface. Here, we show that the abil-
ity of IgG1 antibodies to form hexamers can be enhanced by single point mutations at specific
amino acid positions both at the intermolecular Fc:Fc and the intramolecular CH2–CH3 inter-
face. Several IgG1 mutants, exemplified by E430G and E345K, displayed strongly enhanced
CDC that remained conditional on antigen binding at the target cell. Increased self-association
of these mutants was only apparent at high (10–100 mg/mL) concentrations in solution. This
self-association was fully reversible and did not result in the formation of aggregates. Further-
more, the slight increase in self-association for these mutants did not lead to solution-phase
complement activation in serum or accelerated pharmacokinetics.
Mutations of the Fc:Fc interface residue E345 yielded potent activation of CDC irrespective of
the amino acid substitution. It therefore appears unlikely that mutation-specific interactions drive
hexamerization. We hypothesized that the wild-type E345 side chain might restrict the conforma-
tional freedom of this residue by side chain-specific interactions with neighboring residues.
Although the closest hydrogen bond donor, the H433 backbone amide, seemed too distant for
direct interaction, a water-mediated hydrogen bond could possibly bridge this distance. Both
E345 side chain rigidity and possibly associated water were therefore analyzed for several high-res-
olution, nonmutated Fc structures containing defined water molecules (S6A Fig). Indeed, these
structures displayed limited variation in E345 carboxylic acid positioning, and approximately half
contained a water molecule potentially bridging the E345 carboxylic acid group and the H433
backbone amide. E345 mutations might therefore increase conformational flexibility or potentially
facilitate increased movement of H433 enabling optimized interactions with the opposing Fc.
CDC enhancement was more sidechain-specific for other stimulatory mutations at the Fc:
Fc interface. I253V, S254L, Q311L, and Q311I likely contributed to optimization of the hydro-
phobic consensus region interaction site at the Fc:Fc interface (S6B Fig). Mutations S440Y and
S440W also promoted hexamerization, possibly by stacking their aromatic moieties. However,
hydrogen bonding to opposing Fc backbone atoms may also be important, given the poor effi-
cacy of S440F (S6C Fig).
CH2:CH2 distances can vary well over 10 Å when captured by crystallization of different gly-
can forms [25–27]. We hypothesized that modifying the CH2–CH3 interface could lead to allo-
steric induction of antibody hexamerization via modulation of this dynamic conformational
landscape. Functional screening identified a number of CH2–CH3 interface residues that dis-
played increased CDC efficacy in which residue E430 stood out (S5 Table). Remarkably, substi-
tutions of this glutamic acid to all possible amino acids stimulated CDC, suggesting that new
side chain-specific effects are unlikely explanations for the allosteric stimulation. Rather, the
highly conserved salt bridge formed between CH3 residue E430 and CH2 residue K338 might
limit the population of CH2 domains occupying a hexamerization-favorable state (S6D Fig).
The disruption of the salt bridge alone, however, appeared insufficient, as modification of the
pairing residue K338 only had a very limited effect on CDC (S5 Table).
The glutamic acids at positions 345 and 430 are conserved in all human IgG subclasses.
Since a substitution into any other amino acid results in increased hexamerization and comple-
ment activation, it may therefore be speculated that glutamic acid at these positions may play a
role in restricting exaggerated complement activation. In addition, some substitutions at these
two positions increased the propensity to bind C1q in solution, as measured by a target inde-
pendent C4d ELISA and native MS, and led to increased clearance from the murine circulation.
The prevention of IgG self-association by E345 and E430 might thus enable natural access to a
more extensive fraction of the antibody repertoire expressed as soluble IgG.
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The results described therefore provide a number of amino acid positions in the antibody Fc
region that enhance the ability of IgG molecules to form hexamers, which provide a docking
and activation structure for avid C1 binding and efficient complement activation. The mutants
E430G and E345K exemplify the preferred IgG1 backbones. These mutants enable potent CDC
for a range of antibodies against different targets, while preventing target-independent comple-
ment activation in solution at therapeutically applied mAb concentrations, which are
generally> 20-fold lower than natural IgG1 titers. In designing the enhanced hexamerization
antibody platform, we selected backbones with optimal manufacturability and developability
characteristics including criteria requiring an absence of antigen-independent complement
activation. When applying the hexamerization-enhanced backbones in a novel antibody or Fc-
fusion protein, a careful assessment of safety and potential efficacy will need to be performed
to establish the therapeutic window, as with any new drug. For each specific disease target, it
will therefore be important to determine the potential utility of enhanced IgG hexamerization
as a therapeutic strategy. This potential is envisaged to be dependent on e.g., expression of anti-
gen and its ability to multimerize, the potential downstream effects of multimerization, the
expression of complement regulatory proteins on target cells, the availability of complement
factors, as well as the expression of antigen on normal tissue.
The IgG1 Fc backbones identified provide a novel platform for the generation of therapeu-
tics with enhanced effector functions that only become activated upon target-cell binding and
hexamerization. When compared to protein- and glyco-engineered therapeutic antibody tech-
nologies based on increased binding to effector molecules with “always-on” characteristics, it is
this conditional enhancement that uniquely differentiates this novel platform inspired by the
naturally occurring hexamerization of IgG antibodies.
Materials and Methods
Construction, Expression, and Purification of Antibody Variants
Antibodies were expressed recombinantly in-house using an IgG1 heavy chain with the allo-
type G1m(f), or bought via the pharmacy (ALM, OBN). The following mAbs were used: CD20
mAbs 7D8, 11B8, RTX and OBN [16,28,29], CD38 mAbs IgG1-005 and IgG1-003 [18], EGFR
mAb 2F8 [30], HIV-1 gp120 mAb IgG1-b12 [31], CD52 mAb (ALM) [32]. ALM variant
E345R contained an additional K409R mutation known not to impact CDC.
Codon-optimized antibody genes encoding heavy and light chains (GeneArt, Germany)
were cloned separately into pcDNA3.3 (Life Technologies, US). Mutations were introduced in
heavy chain expression vectors either using Quikchange technology (Agilent Technologies, US),
or via gene-synthesis (Geneart, Germany), at the indicated positions numbered according to EU
nomenclature. Antibodies were expressed in HEK293 FreeStyle cells by transfection of light
chain and heavy chain expression vector DNA using 293fectin essentially, as described [33].
Antibodies were purified by Protein A affinity chromatography (rProtein A FF; GE Healthcare),
dialyzed overnight to PBS, and filter-sterilized over 0.2-μM dead-end filters. The concentration
of purified IgGs was determined by absorbance at 280 nm. Quality assessment of purified anti-
bodies was performed by SDS/PAGE (>90% intact IgG,>95% HC + LC under reducing condi-
tions), ESI-TOFMS (identity confirmation), and HP-SEC (aggregate level<5%). All discussed
proteins were purified and met these quality criteria unless explicitly stated otherwise.
Construction and Expression of Fc-Mutant Antibody Library
A focused library of mutations at the positions indicated in S4 and S5 Tables was generated by
site-directed mutagenesis. Mutations were introduced into the IgG1-005 Fc region using the
Quikchange site-directed mutagenesis kit (Agilent, US). Briefly, for each desired mutation
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position, a forward and a reverse primer encoding a degenerate NNS codon at the desired loca-
tion were used to replicate a full length pcDNA3.3 (Life Technologies, US) plasmid DNA tem-
plate containing the IgG1-005 heavy chain with IgG1m(f) allotype. The resulting DNA
mixtures were digested using DpnI to remove source plasmid DNA and used to transform
Escherichia coli. Plasmid DNA was extracted from bacterial cultures inoculated with colonies
pooled per position, and retransformed into E. coli to obtain clonal colonies.
Mutant plasmid DNA isolated from resulting individual colonies was checked by DNA
sequencing (LGC genomics, Berlin, Germany). Expression cassettes were amplified from hit
picked DNA plasmids by PCR and DNAmixes containing both a mutant heavy and a wild-
type light chain of IgG1-005 were transiently transfected to Freestyle HEK293F cells (Invitro-
gen, US) using 293fectin (Invitrogen, US) essentially as described [33]. Supernatants of trans-
fected cells containing antibody mutants were collected.
Mutant antibody supernatants were screened in CDC assays as follows. 0.1 x 106 Daudi or
Wien 133 cells were preincubated in round-bottom 96-well plates with 1.0 μg/ml of unpurified
antibodies in a total volume of 100 μL for 15 min on a shaker at RT. As controls we included:
40 μL mock transfected HEK293 supernatants or PBS and IgG1-b12 as an isotype control anti-
body. Next, 30 μL normal human serum was added as a source of complement (30% final con-
centration) and incubated in a 37°C incubator for 45 min. The reaction was stopped by putting
the plates on ice, followed by adding 10 μl propidium iodide (PI) and determination of cell
lysis by FACS.
Cell Culture and Reagents
The A431 human epidermoid cell line and DOHH-2, MEC-2, SU-DHL-4, and WSU-NHL
human lymphoma cell lines were obtained from the Deutsche Sammlung von Mikroorganis-
men und Zellkulturen (cell line numbers ACC 91, ACC 47, ACC 500, ACC 495, and ACC 58
respectively; Braunschweig, Germany). ARH-77, Daudi, Raji, Ramos, and WIL2-S cell lines
(human lymphoma) were obtained from the American Type Culture Collection (ATCC no.
CRL-1621, CCL-213, CCL-86 and CRL-1596 respectively; Rockville, MD). Wien 133 cells
(human Burkitt’s lymphoma) were kindly provided by Dr. Geoff Hale (BioAnaLab Limited,
Oxford, UK). Raji-luc cells were generated by electroporation of Raji cells with gWIZ luciferase
(Aldevron, Fargo, ND) and pPur vector (BD Biosciences, Alphen aan de Rijn, The Nether-
lands) in a 4:1 ratio and, after 48 h, puromycin was added for selecting a stably transfected
clone (Raji-luc #2D1). Daudi, Raji, WIL2-S, ARH-77, DOHH-2, Ramos, WSU-NHL, and
SU-DHL-4 were cultured in RPMI 1640 supplemented with 10% heat-inactivated CCS, 1 U/
mL penicillin, 1 μg/mL streptomycin, and 4 mM L-glutamine. Raji-luc #2D1 cells were supple-
mented with 1 μg/mL puromicin. MEC-2 andWien 133 were cultured in IMDM supplemented
with 10% heat-inactivated FCS, 1 U/mL penicillin, and 1 μg/mL streptomycin (all media and
supplements were obtained from Lonza, Vervier, Belgium). HEK293 Freestyle cells were
obtained from Life Technologies (formerly Invitrogen, Paisley, UK). All cell lines were rou-
tinely tested for mycoplasma contamination and generally aliquoted and banked to allow in
vitro assays to be performed from frozen cells instead of continuously cultured systems to
ensure authenticity of the cell lines. Pooled normal human serum (NHS) AB was obtained
from Sanquin (The Netherlands). Primary B cells from CLL patients were obtained from All-
Cells (Alameda, CA).
Animals
Eight- to 11-wk-old female SCID mice (C.B-17/Icr- Prkdcscid) were obtained from Charles
River Laboratories and housed in a barrier unit of the Central Laboratory Animal Facility. The
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mice were kept in IVC cages with water and food provided ad libitum. Mice were checked daily
for clinical signs of disease and discomfort. All animal experiments were performed in compli-
ance with the Dutch animal protection law (WoD) translated from the directives (2010/63/EU)
and if applicable, the Code of Practice “animal experiments for cancer research” (Inspection
V&W, Zutphen, The Netherlands, 1999). The animals were housed and handled in accordance
with good animal practice as defined by FELASA, in an AAALAC and ISO 9001:2000 accred-
ited animal facility. The local animal welfare body as well as the Animal Welfare Committee
Utrecht University (DEC-Utrecht) approved all the animal experiments (2012.II.08.123 for the
pharmacokinetic analysis, and 2011.III.03.036 for in vivo efficacy studies).
ADCC
The ADCC assay was performed as described by Overdijk et al. [34]. Briefly, Raji cells were
labeled with 100 μCi 51Cr (Amersham Biosciences, Uppsala, Sweden) and 4 h ADCC assays
were performed according to standard procedures, using peripheral blood mononuclear cells
(PBMC) from healthy donors as effector cells at a 100:1 effector:target ratio. The percentage
NK cells was determined by staining for anti-CD56 (BD 555516, BD Biosciences, Aalst, Bel-
gium) and analyzing on flow cytometer (FACS canto II, BD Biosciences). FcγRIIa-H131R
(rs1801274) and FcγRIIIa-V158F (rs396991) genotyping in the PBMC were determined by
predesigned SNP genotyping TaqMan SNP assays according to the manufacturer’s protocol
(Thermo Fisher Scientific, Waltham, MA USA).
Capillary Electrophoresis SDS (CE-SDS)
Purity and fragmentation of the samples were analyzed using CE-SDS on the Labchip GXII
(Caliper Life Sciences). Sample preparation was performed in 96-well Bio-Rad HSP9601 plates
using the HT Protein Express Reagent Kit according to manufacturer’s instructions (High Sen-
sitivity protocol) with few modifications. Both nonreduced and reduced samples (addition of
DTT) were prepared and denatured by incubation at 70°C for 10 min. The chip was prepared
according to manufacturer’s instructions, and the samples were run with the HT antibody
analysis 200 high sensitivity settings. Data were analyzed for molecular weight and purity (frac-
tion of total) with Labchip GXII software.
CDC Assay
CDC assays were performed as described [35] with an antibody concentration series or a fixed
antibody concentration and normal human serum (20% final concentration unless indicated
otherwise) as a source of complement. Killing was calculated as fraction TOPRO-iodide+ cells
(%) determined by a Celigo imaging cytometer (Brooks Life Science Systems) for A431 carci-
noma cells, and as the fraction PI+ cells (%) determined by a BD FACSCanto II flow cytometer
for all other cells.
Complement Activation in Normal Human Serum
Complement activation in the absence of target was determined by measuring C4d concentra-
tions, a marker for classical complement pathway activation, after incubating 100 μg antibody
per mL in 90% normal human serum for 1 h at 37°C. C4d concentrations were measured in an
ELISA (MicroVue C4d EIA kit, Quidel Corporation, San Diego, US) according to the manufac-
turer’s instructions.
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Dynamic Light Scattering
Dynamic Light Scattering measurements were performed on a DynaPro Plate Reader II (Wyatt
Technology) with Dynamics 7 software. Samples were applied in duplicate in a 384 well plate
(Black, Round 384 IQ-LV, Aurora Biotechnologies, Cat no. 1011–00110) at 30 μL volume and
covered with paraffin oil. Prior to the measurement the plates were centrifuged for 3 min at
2,500 xg. Samples were kept at 25°C, and 10 acquisitions of each 5 sec were recorded for each
sample with auto-adjustment of attenuator and laser power. The cumulant fit procedure was
used to analyze the data. A refractive index of 1.333 for PBS buffer at 20°C was used and a vis-
cosity of 1.019 cP (standard software values supplied in Dynamics software). The apparent Rh
of mutants was divided by the Rh of wild-type mAb, each averaged over three experiments.
Hollow Fiber Flow Field Flow Fractionation
Hollow Fiber flow Field Flow Fractionation analysis was performed using an Agilent 1100
HPLC and an Eclipse DualTec system (Wyatt, US), monitoring UV at 280 nm (Agilent) and
connected to a multiangle laser light scattering MiniDawn Treos detector (Wyatt, US). 4.0 μL
protein samples of 1.0 mg/mL concentration were separated in 8.7 mMNa2HPO4/1.8 mM
NaH2PO4/200 mMNaCl buffered at pH 7.4 in a 10 kDa PES hollow fiber with a radius of
400 μm and 17 cm length, and performed in 3-fold. Data was processed using Astra software
version 6.1 (Wyatt, US). Cross-flow, focus time, elution time and flow rate optimization for
IgG1-005 as well as data collection were performed by Coriolis Pharma (Martinsried,
Germany).
HP-SEC Analysis
HP-SEC fractionation was performed using a Waters Alliance 2975 separation unit (Waters,
Etten-Leur, The Netherlands) connected to a TSK HP-SEC column (G3000SWxl; Toso Biosci-
ences, via Omnilabo, Breda, The Netherlands), a Waters 2487 dual λ absorbance detector
(Waters), and a Mini Dawn Treos MALS detection unit (Wyatt). 50 μL samples containing
1.25 mg/mL protein were separated at 1 mL/min in 0.1 M Na2SO4 /0.1 M sodium phosphate
buffered at pH 6.8. Results were processed using Empower software version 2002 and
expressed per peak as percentage of total peak area.
Imaged Capillary Isoelectric Focusing (icIEF)
Imaged Capillary Isoelectric Focusing (icIEF) was performed using an iCE280 Analyzer (Con-
vergent Biosciences) according to the manufacturer’s instructions. Samples were not desalted
before use. Methyl Cellulose and pI markers were purchased from Convergent Bioscience, Car-
rier Ampholytes (Pharmalytes) from GE Healthcare. Focusing was performed for 7 min at
3,000 V, and the whole-capillary absorption image was captured by a charge-coupled device
camera. After calibration of the peak profiles, the data were analyzed for pI and fractional area
(%) by EZChrom software.
Mouse Tumor Xenograft Model
5E+06 luciferase expressing Raji cells were injected subcutaneously on the right flank of 8–9
wk old, female C.B-17/IcrPrkdc-scid/CRL mice (Charles-River Laboratories, Maastricht, the
Netherlands). When tumor volume reached an average of 85 mm3, mice were randomized and
treated with a single intraperitoneal dose of 50 μg IgG1 7D8WT, 7D8-E345R, 7D8-K322A or
IgG1-b12 control antibody. Correct antibody administration was monitored by analysis of IgG
levels seven days after treatment. Tumor volume was measured at least twice per week using
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caliper (PLEXX, Elst, The Netherlands) measurements and calculated as 0.52 x (length) x
(width)2.
Native MS
IgG1 oligomerization was studied by native MS as described previously [36]. The constructs
were analyzed in 0.15 M ammonium acetate (pH 7.5) at an antibody concentration of 2 μM.
This protein preparation was obtained by five sequential concentration and dilution steps at
4°C using a centrifugal filter with a cut-off of 10 kDa (Millipore). Samples were sprayed from
borosilicate glass capillaries and analyzed on a modified LCT time-of-flight instrument
(Waters, UK) adjusted for optimal performance in high mass detection [37,38]. Instrument set-
tings were as follows; needle voltage ~1.4 kV, cone voltage ~100 V, source pressure 8.5 mbar.
The extent of oligomerization was estimated by summing the areas under the curves as
described previously [39].
Photospectrometry
Antibody concentrations were determined by UV spectroscopy using a Nanodrop photospect-
rometer (Thermo Scientific, De Meern, Netherlands). The spectrophotometer was adjusted to
baseline using PBS at 280 nm, and the absorbance of duplicate sample preparations were deter-
mined on the spectrophotometer at both 280 nm (A280) and 350 nm (A350). Sample concen-
trations were calculated using Beer’s law, the extinction coefficient for the specific molecule,
and the A280 value.
Pharmacokinetic Analysis
Antibodies (500 μg per mouse) were administered intravenously to groups of mice (n = 3), and
blood samples were drawn from the submandibular or saphenous vein at 10 min, 3 h, and 1, 2,
7, 14, 21, and 28 d after administration. Blood was collected in heparin-containing vials and
centrifuged (5 min at 10,000 × g) to separate plasma from cells. Plasma was transferred to a
new vial and stored at −20°C. Total human IgG concentration in plasma samples was analyzed
by ELISA. Plates were coated with 2 ug/mL m-anti-HuIgG (clone MH16-1 (Sanquin, The
Netherlands) and plasma human IgG was detected by G-a-HuIgG-HRP (109-035-098, Jack-
son). Injected material was included as reference curve. AUC up to day 21 was addressed using
Graphpad Prism and clearance was calculated as (Dose (mg.kg−1)  1,000 / AUC).
PCD
Daudi cells were incubated for 24 h with indicated antibody (1 μg/mL). Percentage PCD mark-
ers were determined using Annexin V (BD Biosciences cat. 556547) and cleaved Caspase 3 apo-
ptosis Kits (BD Biosciences cat. 550914) via flow cytometry (FACS canto II, BD Biosciences)
according to the manufacturer’s protocols (BD Biosciences).
Visualization of Antibody Structure and Modeling of Mutants
Schematic views of the structure of human monoclonal IgG1 antibody b12 were based on the
IgG1-b12 crystal structure deposited under PDB access code 1HZH, but with amino acids
renumbered according to Eu nomenclature [40], using PyMOL version 1.5.0.4 (Schrödinger
LLC). Mutant models were generated by selecting the rotamers with minimal steric clashes
without subsequent energy minimization.
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Supporting Information
S1 Data. Excel spreadsheet containing, in separate sheets, the underlying numerical data
and statistical analyses for Figs 1–7 and S1 Fig to S5 Fig.
(XLSX)
S1 Fig. Structural analysis of CDC inhibiting mutations. (A) Comparison of the IgG1 Fc:Fc
interaction as observed in IgG1-b12 Fc (PDB access code 1HZH, left), with rat FcRn (mid,
3FRU) and with Staphylococcus aureus protein A (right, 1FC2), respectively. FcRn (dark blue:
large FcRn subunit p51; light blue: beta-2 microglobulin) and protein A (light blue) interactions
were modeled by structurally aligning their interacting Fc with 1HZH using DaliLite [41]. (B)
Zoom to IgG consensus interaction site composed of residues 252–255, 380, 428, and 433–436
(according to DeLano et al.) [21]. Residues were colored by median lysis as defined in Fig 3B,
>60% (blue), 30%–60% (orange), or<30% (red). Two views rotated 90 degrees along the y-axis
are indicated. (C) Zoom to the Fc:Fc interface C-terminal β-strand interaction region. Mutants
of all residues 436–440 displayed a median lysis below 30% (defined in Fig 3B; S4 Table).
(EPS)
S2 Fig. Validation of CDC potentiation by IgG1 Fc-domain mutations. (A) CDC of Daudi
cells by wild-type and mutant IgG1-005 antibodies. A representative of three replicate experi-
ments is shown. (B) CDC of Daudi cells by wild-type and mutant RTX antibodies. A represen-
tative of three replicate experiments is shown.
(EPS)
S3 Fig. PK analysis of RTX mutants in SCID mice using three mice per group. Clearance of
a single 500 μg dose of mAb was monitored for 3 wk and is expressed as 1,000  Dose / AUC;
dashed line: average clearance of wild-type RTX.
(EPS)
S4 Fig. Size-distribution analysis of selected IgG mutants. (A) HP-SEC profiles of Protein A-
purified IgG1-005 and mutant antibodies. Left panel: chromatograms staggered at 0.5 AU per
trace along y-axis. Right panel: 50x zoomed chromatograms, staggered at 0.01 AU per trace.
Main peaks at 9.0–9.1 min indicate monomeric species. Aggregate levels for the mutants
(1.2%) were similar to the wild-type (<1%). (B) Hollow fiber flow field flow fractionation
analysis of wild-type IgG1-005 and mutant antibodies. The triple mutant IgG1-005-RGY was
used as a control for the detection of hexameric species.
(EPS)
S5 Fig. Real time stability study of 100 mg/mL 7D8 and mutant antibody solutions formu-
lated in PBS pH 7.4 incubated for three months at 5°C. (A) HP-SEC to determine the frac-
tion of degradation products as a percentage of total protein. Detection limit of 1% is indicated
by a dashed line. (B) Nonreducing CE-SDS analysis for the fraction of intact IgG as a percent-
age of total protein. (C) Reducing CE-SDS analysis for the fraction HC+LC as a percentage of
total protein. (D) Capillary isoelectric focusing analysis for the fraction of acidic species as a
percentage of total protein. (E) Capillary isoelectric focusing analysis for the fraction of basic
species as a percentage of total protein. Detection limit of 2.5% is indicated by a dashed line.
(F) Photospectrometric analysis at 280 nm. (G) Photospectrometric analysis at 350 nm after
100-fold dilution in PBS.
(EPS)
S6 Fig. Structural analysis of CDC-regulating hotspots E345 and E430. (A) CH3 domain-
based structural alignment of IgG1 antibody b12 (1HZH chain K, light green) with high
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resolution IgG Fc crystal structures, zoomed to E345. Arrow indicates oxygen atoms of
E345-proximal water molecules, displayed as spheres. Dark green: 1HZH chain H; chocolate:
4KU1 [25]; dark red: 1H3U [27]; dark pink: 1H3X [27]; dark salmon: 3AY4 [42]; light pink:
3V7M [43]; purple: 4B7I [44]. (B) Molecular zoom of residues at the consensus interaction site
of antibody IgG1-b12 (PDB access code 1HZH). Residues from two interacting Fc-domains
are indicated: one Fc in light green ribbon with side chains indicated as sticks, the other Fc’ in
light blue surface presentation, residues labeled with a prime. Noncarbon atoms were colored
by element (oxygen, red; nitrogen, dark blue). (C) Molecular zoom of residues in the C-termi-
nal β–strands of two interacting Fc-domains (green and blue, respectively) of antibody
IgG1-b12. Mutant models of S440Y (mid) and S440W (right) were generated by selecting the
rotamer with minimal steric hindrance, without further energy minimization. (D) Structural
alignment as defined in (A), zoomed to the E430 (CH3)–K338 (CH2) salt bridge. Note the vari-
ation in CH2 domain positioning relative to the CH3 domain, captured by different crystal iso-
forms.
(EPS)
S1 Table. EC50 (antibody concentration inducing half-maximal lysis) values for CDC of
antibody-opsonized cells.Mean EC50 and SD for CDC of different cell lines opsonized with
wild-type or E345R-mutated antibody and incubated in the presence of human complement
were determined. Numbers of replicates and statistics are shown. (1) Number of experiments.
(2) Mean and (3) standard deviation (SD) were calculated from all experiments. (4) Statistics:
unpaired t test two tailed on log-transformed data (GraphPad Prism 5.01). Significance was
calculated in comparison to the wild-type IgG1 counterpart: (n.a.) not applicable; (n.s.) not sig-
nificant. (5) EC50 indicated as>μg/mL as lysis did not reach 50%. (6) Since EC50 could not be
determined, upper bound of significance was calculated using maximally tested concentration
as lower bound for EC50.
(DOCX)
S2 Table. QiFi analysis of cell surface marker expression. Expression levels of CD20, CD38,
CD52, EGFR, and the mCRPs CD46, CD55, CD59 on cell lines used in this study; n.d.: not
determined. The cell lines are sorted for decreasing CD20:mCRP ratio. Numbers indicate mul-
tiples of thousand molecules per cell.
(DOCX)
S3 Table. Analysis of mouse tumor xenograft growth. Top panel: tumor size monitored by
caliper measurements was used to calculate average tumor size per group. At day 22, the last
day at which all groups were still complete, a nonparametric Mann Whitney analysis was
applied to tumor volumes of the different treatment groups using GraphPad Prism. The hex-
amerization-enhanced antibody 7D8-E345R inhibited tumor growth significantly when com-
pared to the isotype control antibody IgG1-b12 and the complement-deficient mutant
7D8-K322A. Bottom panel: Time to progression (cut-off set at tumor volume>700 mm3) was
analyzed by a Mantel-Cox pairwise comparison test using SPSS. When compared to IgG1-b12
control antibody, only 7D8-345R antibody-inhibited tumor progression significantly.
(DOCX)
S4 Table. IgG1-005 Fc domain mutant library CDC screen using Daudi cells at 1.0 μg/mL
mutant IgG1. The condition was chosen as it gives high CDC (>80%) for the wild-type anti-
body and therefore provides for a screening condition in which inhibition of complement acti-
vation by specific mutations can be assessed. Numbers indicate percentage cell lysis. Lysis and
SD of control antibodies is summarized below the main table; total number of control repli-
cates is indicated in brackets. Controls include: mock transfected HEK293 supernatants, PBS
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and IgG1-b12 as an isotype control antibody.
(DOCX)
S5 Table. IgG1-005 Fc domain mutant library CDC screen using Wien 133 cells at 1.0 μg/
mL mutant IgG1. The condition was chosen as it gives low CDC (<15%) for the wild-type
antibody and provides for a screening condition in which enhancement of complement activa-
tion by specific mutations can be assessed. Numbers indicate percentage cell lysis. Lysis and SD
of control antibodies is summarized below the main table. The total number of control repli-
cates is indicated in brackets. Controls include: mock transfected HEK293 supernatants, PBS,
and IgG1-b12 as an isotype control antibody.
(DOCX)
S6 Table. EC50 (antibody concentration inducing half-maximal lysis) values for CDC of
IgG1-005 antibody variant opsonized cells.Mean EC50 and SD for CDC of Daudi cells opso-
nized with wild-type or mutant IgG1-005 and incubated in the presence of human complement
were determined. Numbers of replicates and statistics are shown. (1) Number of experiments.
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